Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hepatitis HELP
Based on 52,049 articles published since 2007
|||| 10 

These are the 52049 published articles about Hepatitis that originated from Worldwide during 2007-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Hepatitis B vaccines: WHO position paper – July 2017. 2017

Anonymous1631201. · ·Wkly Epidemiol Rec · Pubmed #28685564.

ABSTRACT: -- No abstract --

2 Guideline Recommendations on hepatitis C screening for adults. 2017

Anonymous2271347. · ·CMAJ · Pubmed #28438952.

ABSTRACT: -- No abstract --

3 Guideline Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 1–2 February 2017 meeting. 2017

Anonymous2461115. · ·Wkly Epidemiol Rec · Pubmed #28413874.

ABSTRACT: -- No abstract --

4 Guideline American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. 2017

Jacobson, Ira M / Lim, Joseph K / Fried, Michael W. ·Department of Medicine, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ijacobson@chpnet.org. · Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut. · Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina. ·Gastroenterology · Pubmed #28344022.

ABSTRACT: Chronic hepatitis C virus infection is well-recognized as a common blood-borne infection with global public health impact affecting 3 to 5 million persons in the United States and more than 170 million persons worldwide. Chronic hepatitis C virus infection is associated with significant morbidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma. Current therapies with all-oral direct-acting antiviral agents are associated with high rates of sustained virologic response (SVR), generally exceeding 90%. SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver transplantation, and both liver-related and all-cause mortality. However, a subset of patients who achieve SVR will remain at long-term risk for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related mortality. Limited evidence is available to guide clinicians on which post-SVR patients should be monitored vs discharged, how to monitor and with which tests, how frequently should monitoring occur, and for how long. In this clinical practice update, available evidence and expert opinion are used to generate best practice recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

5 Guideline No. 342-Hepatitis B and Pregnancy. 2017

Castillo, Eliana / Murphy, Kellie / van Schalkwyk, Julie. ·Calgary, AB. · Toronto, ON. · Vancouver, BC. ·J Obstet Gynaecol Can · Pubmed #28284515.

ABSTRACT: OBJECTIVE: To review the epidemiology, natural history, evaluation, and treatment of hepatitis B virus (HBV) infection during pregnancy. This will aid obstetric care providers in counseling their patients regarding perinatal risks and management options available to pregnant women with hepatitis B. OUTCOMES: Outcomes evaluated include thresholds for HBV anti-viral treatment for prevention of perinatal transmission and for invasive procedures during pregnancy for women with hepatitis B infection. EVIDENCE: Medline, EMBASE, and CINAHL were searched for articles in English on subjects related to HBV infection, pregnancy, and perinatal transmission from 1966 to March 2016. Results were restricted to systematic reviews, randomized controlled trials/controlled clinical trials, and observational studies. Other (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical speciality societies. VALIDATION METHODS: The quality of the evidence is rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table 1). Recommendations for practice are ranked according to the method described in this Report. GUIDELINE UPDATE: The guideline will be reviewed 5 years after publication to decide if an update is required. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations. SPONSORS: This guideline was developed with resources funded by the Society of Obstetricians and Gynaecologists of Canada.

6 Guideline Practice Alert: ACIP vaccine update, 2017. 2017

Campos-Outcalt, Doug. ·Medical Director, Mercy Care Plan, Phoenix, AZ, USA. Email:campos-outcaltd@mercycareplan.com. ·J Fam Pract · Pubmed #28249054.

ABSTRACT: HIV infection is now an indication for meningococcus vaccination and HPV vaccine dosing is simpler for patients ⟨15 years.

7 Guideline ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. 2017

Farraye, Francis A / Melmed, Gil Y / Lichtenstein, Gary R / Kane, Sunanda V. ·Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA. · Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. · Division of Gastroenterology, Hospital of the University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. ·Am J Gastroenterol · Pubmed #28071656.

ABSTRACT: Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy. In particular, documentation of up to date vaccinations are crucial as IBD patients are often treated with long-term immune-suppressive therapies and may be at increased risk for infections, many of which are preventable with vaccinations. Health maintenance issues addressed in this guideline include identification, safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer as well as identification of depression and anxiety and smoking cessation. To accomplish these health maintenance goals, coordination between the primary care provider, gastroenterology team and other specialists is necessary.

8 Guideline  Joint Society statement for elimination of viral hepatitis. 2017

Brahm, Javier / Castera, Laurent / Hou, Jinlin / Lindor, Keith. ·Latin American Association for the Study of the Liver. · European Association of the Study of the Liver. · Asian Pacific Association for the Study of the Liver. · American Association for the Study of Liver Disease. ·Ann Hepatol · Pubmed #28051786.

ABSTRACT: -- No abstract --

9 Guideline ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. 2017

Kwo, Paul Y / Cohen, Stanley M / Lim, Joseph K. ·Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA. · Digestive Health Institute, University Hospitals Cleveland Medical Center and Division of Gastroenterology and Liver Disease, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. · Yale Viral Hepatitis Program, Yale University School of Medicine, New Haven, Connecticut, USA. ·Am J Gastroenterol · Pubmed #27995906.

ABSTRACT: Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation determined to be of hepatic origin, testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken. Total bilirubin elevation can occur in either cholestatic or hepatocellular diseases. Elevated total serum bilirubin levels should be fractionated to direct and indirect bilirubin fractions and an elevated serum conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings. A liver biopsy may be considered when serologic testing and imaging fails to elucidate a diagnosis, to stage a condition, or when multiple diagnoses are possible.

10 Guideline Post-exposure prophylaxis guidelines for children and adolescents potentially exposed to HIV. 2017

Bamford, Alasdair / Tudor-Williams, Gareth / Foster, Caroline. ·Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, London, UK. · Department of Paediatric Infectious Diseases, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK. ·Arch Dis Child · Pubmed #27974330.

ABSTRACT: UK guidelines for HIV post-exposure prophylaxis (PEP) in adults have recently been updated. Indications for PEP have been modified and there has been a change in the recommended antiretroviral therapy for adults to a combination of raltegravir with tenofovir and emtricitabine (Truvada). Raltegravir and tenofovir are now available in paediatric formulations and offer improved safety and tolerability over previously recommended ritonavir-boosted lopinavir with zidovudine. This guideline provides recommendations for those caring for children potentially exposed to HIV and other bloodborne viruses in primary care, emergency departments, secondary care and specialist paediatric HIV centres.

11 Guideline [Management following sexual exposure to HIV, HVB and HVC]. 2016

Timsit, F-J / Vernay-Vaisse, C / Derancourt, C / Viraben, R / Chartier, C / Spenatto, N / Anonymous3261106. ·Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. Electronic address: centre.mst@aphp.fr. · CIDAG/CIDDIST MDS Aubagne, 10, allée Antide-Boyer, 13400 Aubagne, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort de France, France. · Service de dermatologie et médecine sociale, pôle santé publique et médecine sociale, hôpital La Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · 24, place Kléber, 67000 Strasbourg, France. · ·Ann Dermatol Venereol · Pubmed #27776810.

ABSTRACT: -- No abstract --

12 Guideline [STD and STI screening]. 2016

Vernay-Vaïsse, C / Spenatto, N / Derancourt, C / Timsit, F-J / Fouéré, S / Pinault, A-L / Anonymous3121106. ·CIDAG/CIDDIST CD 13, DPMISP, 4, quai d'Arenc, CS 70095, 13304 Marseille cedex 02, France. Electronic address: chantal.vernayvaisse@cg13.fr. · Pôle santé publique et médecine sociale, service de dermatologie et médecine sociale, hôpital La-Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort-de-France, Martinique. · Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. · 41, boulevard Henri IV, 75004 Paris, France. · Service de dermatologie, hôpital de Brabois, CHU de Nancy, 5, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. · ·Ann Dermatol Venereol · Pubmed #27773502.

ABSTRACT: -- No abstract --

13 Guideline SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016

Alghamdi, Abdullah S / Alghamdi, Mohammed / Sanai, Faisal M / Alghamdi, Hamdan / Aba-Alkhail, Faisal / Alswat, Khalid / Babatin, Mohammed / Alqutub, Adel / Altraif, Ibrahim / Alfaleh, Faleh. ·Department of Medicine, Gastroenterology Unit, King Fahad Hospital, Jeddah, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Fahd Military Complex, Dhahran, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia. · Department of Hepatobiliary Sciences and Liver Transplantation King Abdulaziz Medical City, and King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. · Department of Medicine, Gastroenterology unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia. · Department of Medical Specialties, Gastroenterology and Hepatology Section, King Fahad Medical City, Riyadh, Saudi Arabia. ·Saudi J Gastroenterol · Pubmed #27538727.

ABSTRACT: -- No abstract --

14 Guideline British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. 2016

Warren, R B / Weatherhead, S C / Smith, C H / Exton, L S / Mohd Mustapa, M F / Kirby, B / Yesudian, P D. ·The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD, U.K. · Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, U.K. · St John's Institute of Dermatology, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, U.K. · British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, U.K. · St Vincent's University Hospital, Elm Park, Dublin, Ireland. · Glan Clwyd Hospital, Sarn Lane, Rhyl, LL18 5UJ, U.K. ·Br J Dermatol · Pubmed #27484275.

ABSTRACT: -- No abstract --

15 Guideline APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016

Omata, Masao / Kanda, Tatsuo / Wei, Lai / Yu, Ming-Lung / Chuang, Wang-Long / Ibrahim, Alaaeldin / Lesmana, Cosmas Rinaldi Adithya / Sollano, Jose / Kumar, Manoj / Jindal, Ankur / Sharma, Barjesh Chander / Hamid, Saeed S / Dokmeci, A Kadir / Al-Mahtab, Mamun / McCaughan, Geofferey W / Wasim, Jafri / Crawford, Darrell H G / Kao, Jia-Horng / Yokosuka, Osamu / Lau, George K K / Sarin, Shiv Kumar. ·Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. momata-tky@umin.ac.jp.; The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. momata-tky@umin.ac.jp. · Graduate School of Medicine, Chiba University, Chiba, Japan. · Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China. · Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. · Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. · GI/Liver Division, Department of Internal Medicine, University of Benha, Banha, Egypt. · Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. · University Santo Tomas Hospital, Manila, Philippines. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh. · Royal Prince Alfred Hospital, Centenary Institute, University of Sydney, Sydney, Australia. · University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia. · National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. · The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China. ·Hepatol Int · Pubmed #27229718.

ABSTRACT: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

16 Guideline APASL consensus statements and recommendation on treatment of hepatitis C. 2016

Omata, Masao / Kanda, Tatsuo / Wei, Lai / Yu, Ming-Lung / Chuang, Wang-Long / Ibrahim, Alaaeldin / Lesmana, Cosmas Rinaldi Adithya / Sollano, Jose / Kumar, Manoj / Jindal, Ankur / Sharma, Barjesh Chander / Hamid, Saeed S / Dokmeci, A Kadir / Mamun-Al-Mahtab, ? / McCaughan, Geofferey W / Wasim, Jafri / Crawford, Darrell H G / Kao, Jia-Horng / Yokosuka, Osamu / Lau, George K K / Sarin, Shiv Kumar. ·Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-Shi, Yamanashi, 400-8506, Japan. hepint_omata@yahoo.co.jp.; The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hepint_omata@yahoo.co.jp. · Graduate School of Medicine, Chiba University, Chiba, Japan. · Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China. · Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. · Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. · GI/Liver Division, Department of Internal Medicine, University of Benha, Benha, Egypt. · Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. · University Santo Tomas Hospital, Manila, Philippines. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh. · Centenary Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. · School of Medicine, University of Queensland, Woolloongabba, QLD, 4102, Australia. · National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. · The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China. ·Hepatol Int · Pubmed #27130427.

ABSTRACT: The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409-435, 2012)". The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.

17 Guideline KASL clinical practice guidelines: management of hepatitis C. 2016

Anonymous360951. · ·Clin Mol Hepatol · Pubmed #27044763.

ABSTRACT: -- No abstract --

18 Guideline KASL clinical practice guidelines: management of chronic hepatitis B. 2016

Anonymous350951. · ·Clin Mol Hepatol · Pubmed #27044762.

ABSTRACT: -- No abstract --

19 Guideline Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. 2016

Crabb, David W / Bataller, Ramon / Chalasani, Naga P / Kamath, Patrick S / Lucey, Michael / Mathurin, Philippe / McClain, Craig / McCullough, Arthur / Mitchell, Mack C / Morgan, Timothy R / Nagy, Laura / Radaeva, Svetlana / Sanyal, Arun / Shah, Vijay / Szabo, Gyongyi / Anonymous601212. ·Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, School of Medicine, Indianapolis, Indiana. Electronic address: dcrabb@iu.edu. · Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. · Division of Gastroenterology and Hepatology Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. · Gastroenterology Research Unit, Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. · Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin, Madison, Wisconsin. · Service Maladie de l'Appareil Digestif and INSERM U995 Univ Lille 2, CHRU Lille, France. · Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky. · Departments of Gastroenterology, Hepatology and Transplant Surgery, Cleveland Clinic, Cleveland, Ohio. · Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas. · VA Long Beach Healthcare System, Long Beach, California. · Department of Pathobiology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio. · Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. · Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, Virginia. · Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. · ·Gastroenterology · Pubmed #26921783.

ABSTRACT: -- No abstract --

20 Guideline ACG Clinical Guideline: Liver Disease and Pregnancy. 2016

Tran, Tram T / Ahn, Joseph / Reau, Nancy S. ·Department of Medicine, Liver Transplant, Cedars Sinai Medical Center, Los Angeles, California, USA. · Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA. · Department of Medicine, Rush University, Chicago, Illinois, USA. ·Am J Gastroenterol · Pubmed #26832651.

ABSTRACT: Consultation for liver disease in pregnant women is a common and oftentimes vexing clinical consultation for the gastroenterologist. The challenge lies in the need to consider the safety of both the expectant mother and the unborn fetus in the clinical management decisions. This practice guideline provides an evidence-based approach to common diagnostic and treatment challenges of liver disease in pregnant women.

21 Guideline AISF position paper on liver disease and pregnancy. 2016

Anonymous380947 / Anonymous390947. · ·Dig Liver Dis · Pubmed #26747754.

ABSTRACT: The relationship between liver disease and pregnancy is of great clinical impact. Severe liver disease in pregnancy is rare; however, pregnancy-related liver disease is the most frequent cause of liver dysfunction during pregnancy and represents a severe threat to foetal and maternal survival. A rapid differential diagnosis between liver disease related or unrelated to pregnancy is required in women who present with liver dysfunction during pregnancy. This report summarizes the recommendation of an expert panel established by the Italian Association for the Study of the Liver (AISF) on the management of liver disease during pregnancy. The article provides an overview of liver disease occurring in pregnancy, an update on the key mechanisms involved in its pathogenesis, and an assessment of the available treatment options. The report contains in three sections: (1) specific liver diseases of pregnancy; (2) liver disease occurring during pregnancy; and (3) pregnancy in patients with pre-existing chronic liver disease. Each topic is discussed considering the most relevant data available in literature; the final statements are formulated according to both scientific evidence and clinical expertise of the involved physicians, and the AISF expert panel recommendations are reported.

22 Guideline Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. 2016

Lagging, Martin / Wejstål, Rune / Norkrans, Gunnar / Karlström, Olle / Aleman, Soo / Weiland, Ola / Castedal, Maria / Josephson, Filip / Anonymous8361243. ·a Department of Infectious Medicine , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden. · a Department of Infectious Medicine , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.; b Swedish Reference Group for Antiviral Therapy (RAV) , Sweden. · c Medical Products Agency , Uppsala , Sweden. · d Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden. · e Transplant Institute, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden. · ·Infect Dis (Lond) · Pubmed #26624849.

ABSTRACT: In a recent expert meeting, Swedish recommendations for the treatment of HCV infection were updated. An interferon-free combination of direct-acting antiviral agents was recommended as the first line standard-of-care treatment for chronic HCV infection. Interferon-based therapy should be considered as a second line option after an individual benefit-risk assessment. Treatment is strongly recommended for HCV infected patients with bridging fibrosis or cirrhosis (Metavir stages F3-4), before and after liver transplantation, and in the presence of extra-hepatic manifestations. Additionally, patients with moderate liver fibrosis (stage F2) as well as women in need of in vitro fertilisation should be prioritised for therapeutic intervention. Treatment indications for people who inject drugs, children, chronic kidney disease and HIV co-infection are also discussed.

23 Guideline Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. 2016

Sarin, S K / Kumar, M / Lau, G K / Abbas, Z / Chan, H L Y / Chen, C J / Chen, D S / Chen, H L / Chen, P J / Chien, R N / Dokmeci, A K / Gane, Ed / Hou, J L / Jafri, W / Jia, J / Kim, J H / Lai, C L / Lee, H C / Lim, S G / Liu, C J / Locarnini, S / Al Mahtab, M / Mohamed, R / Omata, M / Park, J / Piratvisuth, T / Sharma, B C / Sollano, J / Wang, F S / Wei, L / Yuen, M F / Zheng, S S / Kao, J H. ·Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. shivsarin@gmail.com. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.; The Institute of Translational Hepatology, Beijing, China. · Department of Hepatogastroenterlogy, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. · Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. · Genomics Research Center, Academia Sinica, National Taiwan University, Taipei, Taiwan. · Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. · Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. · Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. · Liver Research Unit, Chang Gung Memorial Hospital and University, Chilung, Taiwan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. · Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Guangzhou, China. · Department of Medicine, Aga Khan University, Karachi, Pakistan. · Beijing Friendship Hospital, Capital Medical University, Beijing, China. · , Seoul, Korea. · Department of Medicine, University of Hong Kong, Hong Kong, China. · Internal Medicine Asan Medical Center, Seoul, Korea. · Division of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore. · Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia. · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. · Department of Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia. · Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. · Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. · NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Songkhla, Thailand. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, University of Santo Tomas, Manila, Philippines. · Treatment and Research Center for Infectious Diseases, Beijing 302 Hospital, Beijing, China. · Peking University Hepatology Institute, Beijing, China. · Division of Gastroenterology and Hepatology, Department of Medicine, University of Hong Kong, Pofulam, Hong Kong. · Department of Hepatobiliary and Pancreatic Surgery, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China. · Graduate Institute of Clinical Medicine and Hepatitis Research Center, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. ·Hepatol Int · Pubmed #26563120.

ABSTRACT: Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts' personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

24 Guideline HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. 2016

Reau, Nancy / Fried, Michael W / Nelson, David R / Brown, Robert S / Everson, Gregory T / Gordon, Stuart C / Jacobson, Ira M / Lim, Joseph K / Pockros, Paul J / Reddy, K Rajender / Sherman, Kenneth E. ·Rush University Medical Center, Chicago, IL, USA. · University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · University of Florida, Gainesville, FL, USA. · Weill Cornell Medical College, New York, NY, USA. · University of Colorado, Aurora, CO, USA. · Henry Ford Medical Center, Detroit, MI, USA. · Yale University School of Medicine, New Haven, CT, USA. · Scripps Translational Science Institute, La Jolla, CA, USA. · University of Pennsylvania, Philadelphia, PA, USA. · University of Cincinnati College of Medicine, Cincinnati, OH, USA. ·Liver Int · Pubmed #26509462.

ABSTRACT: BACKGROUND & AIMS: HCV Council 2014, like its predecessor HCV Council 2011, assembled leading clinicians and researchers in the field of hepatitis C to critically evaluate current data regarding best practices for managing patients with chronic hepatitis C virus (HCV). METHODS: Clinical practice statements were developed that reflect the areas of potential controversy with high clinical impact. Faculty members were responsible for reviewing the literature to support or reject these statements. After a review and comprehensive discussion of the data, the HCV Council faculty voted on the nature of the evidence and the level of support for each statement. RESULTS: The results of the detailed analysis with expert opinion are summarized in this article. CONCLUSION: Numerous questions regarding optimal management of certain populations and clinical scenarios remain unanswered. The discussion in the article provides a summary of evidenced-based expert opinion that may help guide clinicians as additional information is developed.

25 Guideline Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. 2015

Bittencourt, Paulo Lisboa / Cançado, Eduardo Luiz Rachid / Couto, Cláudia Alves / Levy, Cynthia / Porta, Gilda / Silva, Antônio Eduardo Benedito / Terrabuio, Debora Raquel Benedita / Anonymous4170861 / Carvalho Filho, Roberto José de / Chaves, Dalton Marques / Miura, Irene Kazue / Codes, Liana / Faria, Luciana Costa / Evangelista, Andreia Silva / Farias, Alberto Queiroz / Gonçalves, Luciana Lofêgo / Harriz, Michele / Lopes Neto, Edmundo Pessoa A / Luz, Gustavo Oliveira / Oliveira, Patrícia / Oliveira, Elze Maria Gomes de / Schiavon, Janaina Luz Narciso / Seva-Pereira, Tiago / Parise, Edison Roberto. ·Hospital Português, Salvador, BA, Brazil. · Faculdade de Medicina, Universidade de São Paulo, SP, Brazil. · Faculdade de Medicina, Universidade Federal de Minas Gerais, MG, Brazil. · University of Miami, USA. · Faculdade de Medicina, Universidade Federal de São Paulo, SP, Brazil. · · Hospital Israelita Albert Einstein, SP, Brazil. · Universidade Federal do Espírito Santo, Vitória, ES, Brazil. · Hospital Universitário, Faculdade de Medicina, Universidade Federal de Espírito Santo, ES, Brazil. ·Arq Gastroenterol · Pubmed #26959804.

ABSTRACT: In order to draw evidence-based recommendations concerning the management of autoimmune diseases of the liver, the Brazilian Society of Hepatology has sponsored a single-topic meeting in October 18th, 2014 at São Paulo. An organizing committee comprised of seven investigators was previously elected by the Governing Board to organize the scientific agenda as well as to select twenty panelists to make a systematic review of the literature and to present topics related to the diagnosis and treatment of autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and their overlap syndromes. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of those recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present paper is the final version of the reviewed manuscript organized in topics, followed by the recommendations of the Brazilian Society of Hepatology.

Next